Centre Forms Three-Member Committee to Review Pharmaceutical Marketing Regulations

The Department of Pharmaceuticals has formed a three-member committee to evaluate the effectiveness of existing frameworks governing pharmaceutical marketing practices. The panel has been tasked with recommending measures to strengthen oversight, which includes examining the possibility of introducing stronger regulatory or statutory provisions.

This development follows government assessments into whether the current systems for preventing unethical marketing by pharmaceutical companies are adequate, or if a more stringent legal framework is necessary. The committee's mandate involves a comprehensive examination of issues related to unethical marketing, alongside assessing whether current monitoring, oversight, and enforcement mechanisms ensure proper compliance.

The panel is specifically directed to identify ways to improve transparency, accountability, and effective compliance within the sector. Its terms of reference include recommending appropriate regulatory, statutory, or other legal measures as deemed necessary.

The committee is chaired by Dr M Srinivas, Member of NITI Aayog. The other members include former Union Health Secretary Preeti Sudan and Dr Naresh Trehan, Chairman and Managing Director of Medanta.

The panel will review the functioning of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP). The code serves as a mandatory regulatory framework governing drug promotion, the conduct of medical representatives, and interactions between pharmaceutical companies and healthcare professionals (HCPs) to eliminate unethical practices and misleading claims. Originally introduced in 2015 as a voluntary, industry-led self-regulatory mechanism, the code was subsequently replaced by UCPMP 2024, which is currently in operation.

The UCPMP is designed to ensure that pharmaceutical product promotion remains accurate, balanced, and evidence-based. It also seeks to prevent prescribing and treatment decisions from being improperly influenced by gifts, financial inducements, or other benefits offered by pharmaceutical companies.

Before finalising its recommendations, the committee will consult relevant stakeholders, technical and professional experts, institutions, and other bodies. The panel has been instructed to submit its final report to the Department of Pharmaceuticals within two months of its first meeting.

Any subsequent changes to the regulatory framework will depend entirely on the committee's recommendations and the government's subsequent decisions. However, the ongoing review could lead to a broader examination of whether current oversight mechanisms for pharmaceutical marketing practices are sufficient or if additional legal provisions are required to improve compliance and accountability.

"The establishment of this high-level committee signals a definitive move towards stricter regulatory oversight in the pharmaceutical sector. For businesses operating in healthcare and life sciences, compliance and transparency are no longer just internal guidelines but critical operational requirements. Companies will need to closely monitor these regulatory shifts, as any move toward a statutory legal framework will significantly impact marketing practices, stakeholder interactions, and overall corporate accountability across the industry." — Dr. Shishir Gupta, Founder & CEO, StartupLanes